5D3 is a new high-affinity murine monoclonal antibody specific for prostate-specific membrane antigen (PSMA). PSMA is a target for the imaging and therapy of prostate cancer. 111In-labeled antibodies have been used as surrogates for 177Lu/90Y-labeled therapeutics. We characterized 111In-DOTA-5D3 by SPECT/CT imaging, tissue biodistribution studies, and dosimetry. Methods: Radiolabeling, stability, cell uptake, and internalization of 111In-DOTA-5D3 were performed by established techniques. Biodistribution and SPECT imaging were done on male nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice bearing human PSMA(+) PC3 PIP and PSMA(-) PC3 flu prostate cancer xenografts on the upper right and left flanks, respectively, at 2, 24, 48, 72, and 192 h after injection. Biodistribution was also evaluated in tumor-free, healthy male CD-1 mice. Blocking studies were performed by coinjection of a 10-fold and 50-fold excess of 5D3 followed by biodistribution at 24 h to determine PSMA binding specificity. The absorbed radiation doses were calculated on the basis of murine biodistribution data, which were translated to a human adult man using organ weights as implemented in OLINDA/EXM. Results: 111In-DOTA-5D3 was synthesized with specific activity of approximately 2.24 ± 0.74 MBq/μg (60.54 ± 20 μCi/μg). Distribution of 111In-DOTA-5D3 in PSMA(+) PC3 PIP tumor peaked at 24 h after injection and remained high until 72 h. Uptake in normal tissues, including the blood, spleen, liver, heart, and lungs, was highest at 2 h after injection. Coinjection of 111In-DOTA-5D3 with a 10- and 50-fold excess of nonradiolabeled antibody significantly reduced PSMA(+) PC3 PIP tumor and salivary gland uptake at 24 h but did not reduce uptake in kidneys and lacrimal glands. Significant clearance of 111In-DOTA-5D3 from all organs occurred at 192 h. The highest radiation dose was received by the liver (0.5 mGy/MBq), followed by the spleen and kidneys. Absorbed radiation doses to the salivary and lacrimal glands and bone marrow were low. Conclusion: 111In-DOTA-5D3 is a new radiolabeled antibody for imaging and a surrogate for therapy of malignant tissues expressing PSMA.
5D3 is a new high-affinity murine monoclonal antibody specific for prostate-specific membrane antigen (PSMA). PSMA is a target for the imaging and therapy of prostate cancer. 111In-labeled antibodies have been used as surrogates for 177Lu/90Y-labeled therapeutics. We characterized 111In-DOTA-5D3 by SPECT/CT imaging, tissue biodistribution studies, and dosimetry. Methods: Radiolabeling, stability, cell uptake, and internalization of 111In-DOTA-5D3 were performed by established techniques. Biodistribution and SPECT imaging were done on male nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice bearing humanPSMA(+) PC3PIP and PSMA(-) PC3flu prostate cancer xenografts on the upper right and left flanks, respectively, at 2, 24, 48, 72, and 192 h after injection. Biodistribution was also evaluated in tumor-free, healthy male CD-1 mice. Blocking studies were performed by coinjection of a 10-fold and 50-fold excess of 5D3 followed by biodistribution at 24 h to determine PSMA binding specificity. The absorbed radiation doses were calculated on the basis of murine biodistribution data, which were translated to a human adult man using organ weights as implemented in OLINDA/EXM. Results: 111In-DOTA-5D3 was synthesized with specific activity of approximately 2.24 ± 0.74 MBq/μg (60.54 ± 20 μCi/μg). Distribution of 111In-DOTA-5D3 in PSMA(+) PC3PIPtumor peaked at 24 h after injection and remained high until 72 h. Uptake in normal tissues, including the blood, spleen, liver, heart, and lungs, was highest at 2 h after injection. Coinjection of 111In-DOTA-5D3 with a 10- and 50-fold excess of nonradiolabeled antibody significantly reduced PSMA(+) PC3PIPtumor and salivary gland uptake at 24 h but did not reduce uptake in kidneys and lacrimal glands. Significant clearance of 111In-DOTA-5D3 from all organs occurred at 192 h. The highest radiation dose was received by the liver (0.5 mGy/MBq), followed by the spleen and kidneys. Absorbed radiation doses to the salivary and lacrimal glands and bone marrow were low. Conclusion: 111In-DOTA-5D3 is a new radiolabeled antibody for imaging and a surrogate for therapy of malignant tissues expressing PSMA.
Authors: Peter M Smith-Jones; Shankar Vallabhajosula; Vincent Navarro; Diego Bastidas; Stanley J Goldsmith; Neil H Bander Journal: J Nucl Med Date: 2003-04 Impact factor: 10.057
Authors: Sangeeta Ray Banerjee; Zhengping Chen; Mrudula Pullambhatla; Ala Lisok; Jian Chen; Ronnie C Mease; Martin G Pomper Journal: Bioconjug Chem Date: 2016-05-09 Impact factor: 4.774
Authors: Michael C Haffner; Johannes Laimer; Alcides Chaux; Georg Schäfer; Peter Obrist; Andrea Brunner; Irmgard E Kronberger; Klaus Laimer; Bora Gurel; Johann-Benedikt Koller; Christof Seifarth; Bettina Zelger; Helmut Klocker; Michael Rasse; Wolfgang Doppler; Neil H Bander Journal: Mod Pathol Date: 2012-03-30 Impact factor: 7.842
Authors: Shankar Vallabhajosula; Stanley J Goldsmith; Klaus A Hamacher; Lale Kostakoglu; Shota Konishi; Mathew I Milowski; David M Nanus; Neil H Bander Journal: J Nucl Med Date: 2005-05 Impact factor: 10.057
Authors: Andrea K Miyahira; Kenneth J Pienta; Michael J Morris; Neil H Bander; Richard P Baum; Wolfgang P Fendler; William Goeckeler; Michael A Gorin; Hartwig Hennekes; Martin G Pomper; Oliver Sartor; Scott T Tagawa; Scott Williams; Howard R Soule Journal: Prostate Date: 2018-05-01 Impact factor: 4.104
Authors: Colin T Huang; Xin Guo; Cyril Bařinka; Shawn E Lupold; Martin G Pomper; Kathleen Gabrielson; Venu Raman; Dmitri Artemov; Sudath Hapuarachchige Journal: Mol Pharm Date: 2020-08-17 Impact factor: 4.939
Authors: Ethel J Ngen; Ying Chen; Babak Behnam Azad; Srikanth Boinapally; Desmond Jacob; Ala Lisok; Chentian Shen; Mir S Hossain; Jiefu Jin; Zaver M Bhujwalla; Martin G Pomper; Sangeeta R Banerjee Journal: Nanotheranostics Date: 2021-01-19
Authors: Eline A M Ruigrok; Nicole S Verkaik; Erik de Blois; Corrina de Ridder; Debra Stuurman; Stefan J Roobol; Dik C Van Gent; Marion de Jong; Wytske M Van Weerden; Julie Nonnekens Journal: Int J Mol Sci Date: 2022-07-21 Impact factor: 6.208
Authors: Sangeeta Ray Banerjee; Ala Lisok; Il Minn; Anders Josefsson; Vivek Kumar; Mary Brummet; Srikanth Boinapally; Cory Brayton; Ronnie C Mease; George Sgouros; Robert F Hobbs; Martin G Pomper Journal: J Nucl Med Date: 2020-11-27 Impact factor: 10.057
Authors: Zora Novakova; Nikola Belousova; Catherine A Foss; Barbora Havlinova; Marketa Gresova; Gargi Das; Ala Lisok; Adam Prada; Marketa Barinkova; Martin Hubalek; Martin G Pomper; Cyril Barinka Journal: Int J Mol Sci Date: 2020-09-12 Impact factor: 5.923